Skip to main content
OpenTrials
Completed

NCT Number: NCT01847807

The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Lanzhou University Second Hospital

Lanzhou, Gansu, 730030, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 years or older, meet the diagnostic criteria of MS
  • non-allergic with the astragalus
  • agree to conduct clinical trials and those who signed the informed consent

Exclusion criteria

  • patients with resistant hypertension
  • renal disease requiring dialysis
  • heart failure NYHA ⅢorⅣ;
  • complications of diabetes
  • arteritis
  • cancer
  • thyroid disease
  • unstable coronary heart disease
  • peripheral vascular disease
  • acute cerebral vascular disease11.pregnancy、 planned pregnancy
  • patients with anti-oxidants
  • acute infection
  • other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.

Treatment and study plan

low dose Astragalus

Drug

high dose astagalus

Drug

Primary outcomes

  1. index of cardiac function

    Time frame: one year

    ues echocardiography to measure the cardiac function

Secondary outcomes

  1. blood pressure

    Time frame: one year

Other outcomes

  1. kidney function

    Time frame: one year

  2. Central Blood Pressure

    Time frame: one year

  3. Ankle Brachial Index

    Time frame: one year

Sponsors and collaborators

Lead sponsor

LanZhou University

Other

Registry information

Official study title

The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome

Important dates

Study start
2011
Primary completion
2015
First posted
May 7, 2013
Registry last updated
Oct 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.